Children with diffuse midline glioma who took Keppra lived a median of 20.96 months, compared with 9.92 months for those who did not, a new study found.
|Videos|January 5, 2017
Miracles Do Happen in GBM
Author(s)Dellann Elliott Mydland
Dellann Elliott Mydland, founder and president of the EndBrainCancer Initiative and 2016 GBM Hero, discusses how miracles do happen in the world of glioblastoma multiforme (GBM), and people survive.
Advertisement
Dellann Elliott Mydland, founder and president of the EndBrainCancer Initiative and 2016 GBM Hero, discusses how miracles do happen in the world of glioblastoma multiforme (GBM), and people survive.
It is crucial to have hope when facing this type of brain tumor, and those who survive often have a top brain surgeon, have their tissue saved and get into clinical trials or new treatment quicker. Through EndBrainCancer's Direct Connect program, the organization is hoping to make this a reality for more patients.
Advertisement
Related to this article
Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.
Advertisement
Advertisement
Trending on CURE
1
5 Years of Leukemia Advances: A Timeline of FDA Approvals and What They Mean for Patients
2
3 More Lung Cancer Breakthroughs From WCLC 2026
3
Blood Cancer Treatments in the FDA Pipeline: What Could Come Next
4
Oncology Nurse Leader Brings Stem Cell Transplant Care Closer to Home
5